Search Results Label68 results found
Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.
Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives
Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.
Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA)
Seqirus appoints Roberta Duncan as new program lead to drive sa-mRNA technology advancement. Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza.
Seqirus strengthens U.K. influenza vaccine response as high-speed fill and finish facility begins rolling 30 million doses in Liverpool
First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool.
EU Flu Day 2021 – Seqirus joins experts’ calls to boost vaccine uptake ahead of a second influenza season during the COVID-19 pandemic
A panel of leading international experts discuss the challenges of the oncoming influenza season at this year’s EU Flu Day
Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats.
The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to
NEJM study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years of age